R&D News | pharmaphorum

News

Kintor hits back at press criticism of COVID drug with US tr...

The China-based biotech Kintor has hit back at press criticism of its potential COVID drug proxalutamide, releasing further details of its US phase 3 development plan.

News

Elliott Management could force out GSK CEO Walmsley, investo...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake

News

Incyte preps second filing for ruxolitinib cream after vitil...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

News

Novo Nordisk moves chronic kidney disease drug ziltivekimab ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

News

Medicago, GSK's plant-made COVID jab clears phase 2

Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available "by e

News

Biogen's eye disease gene therapy fails ahead of FDA Alzheim...

Biogen has downbeat news about its gene therapy for the rare inherited eye disease, X-linked retinitis pigmentosa, announcing the shot failed to meet its target in a phase 2/3 study.

Kintor hits back at press criticism of COVID drug with US tr...

Elliott Management could force out GSK CEO Walmsley, investo...

Incyte preps second filing for ruxolitinib cream after vitil...

Novo Nordisk moves chronic kidney disease drug ziltivekimab ...

Medicago, GSK's plant-made COVID jab clears phase 2

Biogen's eye disease gene therapy fails ahead of FDA Alzheim...

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks